What does manual batch record review really cost pharmaceutical manufacturers?

The cost is not limited to the hours a QA reviewer spends going through a batch record. It includes the QA capacity tied up in routine verification, rework when records come back with issues, and the time a completed batch remains in the release process. 

As manufacturing operations scale, these costs become harder to ignore. 

Some findings require experienced QA judgement. Others are routine checks against predefined requirements. 

The cost problem arises when both require the same amount of manual effort. 

A useful starting point is simple: 

Before accounting for rework, follow-ups, or release delays, 6,000 hours of qualified capacity were dedicated to batch record review. 

The most expensive part of manual review may not appear in the QA budget. 

Every hour spent checking routine documentation is an hour that cannot be spent on: 

The increasing pressure on pharmaceutical producers to increase efficiency without sacrificing quality makes this more pertinent. 

Product quality and batch release were recognized as important areas of opportunity in a 2025 thorough evaluation of digital technologies in pharmaceutical production. However, a major implementation hurdle was the lack of qualified workers. 

The implication is straightforward: qualified quality expertise is a capacity constraint. 

That creates another cost when review becomes a bottleneck. 

Longer review cycles can mean: 

Industry experience supports the operational impact. EY describes Review by Exception as a way to reduce manual scrutiny and batch review cycle time, with the potential to move review from days toward hours.  

Recent industry examples also show that digital batch-record initiatives can have measurable financial impact. Lupin reported INR 12 million in annual savings following implementation of electronic batch records at one manufacturing unit, alongside reduced manual documentation and improved automated checks.  

That doesn't mean every manufacturer will achieve the same savings. It does show why the economics of documentation and review deserve to be measured. 

Start with the numbers already available internally: 

1. Annual batch volume 

How many BMRs does the site review? 

2. Average review time 

How many QA hours does each batch require?  

3. Fully loaded QA cost 

Include salary, benefits, and relevant overhead. 

4. Rework rate 

How often does a record return to manufacturing or another function for correction or clarification? 

5. Release-cycle impact 

How much time passes between manufacturing completion and final disposition? 

This creates a more useful business case than an estimated "cost per batch." It shows how much QA capacity is consumed and where the largest opportunities exist. 

 

The objective should not be to automate the quality decision. 

It is to reduce the amount of routine verification that requires manual effort. 

AI-powered batch record validation can process documentation, perform defined checks, identify potential exceptions, and provide the relevant evidence to QA. The reviewer can then focus on findings that require assessment and judgement. 

The business case is therefore not simply fewer manual checks. 

It is more QA capacity, less rework, and less time spent waiting for routine review. 

For manufacturers evaluating that opportunity, the first step is not buying another system. It is calculating what manual BMR review is already costing the organization. 

Looking to reduce the cost of manual BMR review? 

Explore Saxon AI's Pharma QC Audit Agent to see how AI-powered automation can help review batch records, identify potential exceptions, and reduce the manual effort involved in QA review.